PTGX Protagonist Therapeutics, Inc
Price Chart
Executive Summary
CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting a massive Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus, EPS $0.05 vs. -$0.65 consensus). The sales follow the FDA approval of ICOTYDE and a $200M rusfertide opt-out payment, but the CEO's $7.5M sale at ~$100/share — near all-time highs — raises questions about insider conviction at current valuation. At $11.7M total open-market sales, this represents ~0.17% of PTGX's $6.7B market cap, which is modest but notable given the CEO's participation and the post-earnings timing.
Key Financial Metrics
Actionable Insight
The CEO's $7.5M sale at $100 is the largest insider sale in the trailing 30-day period ($11.9M total). While the company just reported transformative earnings, insider selling at these levels suggests limited near-term upside conviction. Monitor for additional insider sales or any lockup expiration disclosures. The stock's 89% analyst bullish rating may face headwinds if insiders continue to reduce positions.
Key Facts
- CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026
- Director Bryan Giraudo sold 36,000 shares at $100.14 for $3.61M on May 7, 2026
- Total open-market sales: $11.71M (0.17% of $6.7B market cap)
- Sales occurred 2-7 days after Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus)
- CEO also exercised 150,000 options at $0 and $21.58 strike prices (non-cash events)
- Stock is trading near all-time highs following ICOTYDE FDA approval and $200M milestone payment
Financial Impact
Insider sales of $11.71M represent 0.17% of market cap — modest but notable given CEO participation
Risk Factors
- CEO selling near all-time highs may signal peak valuation sentiment
- Further insider sales could pressure stock price
- Post-earnings momentum may fade without additional catalysts
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTGX-1778628514248 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Institutional Cluster
| $109.64 awaiting T+5 | awaiting T+5 | — | $109.78 (+0.13%) |
|
May 12, 2026
4w ago
|
144
| $103.88 $98.37 | ▲ +5.30% | ▲ +4.15% | $109.78 (−5.68%) |
|
May 8, 2026
5w ago
|
Insider Cluster
| $99.36 $105.55 | ▲ +6.23% | ▲ +4.77% | $109.78 (+10.49%) |
|
May 8, 2026
5w ago
|
Insider Cluster
| $99.36 $105.55 | ▲ +6.23% | ▲ +4.77% | $109.78 (+10.49%) |
|
May 5, 2026
5w ago
|
8-K
| $103.97 $99.95 | ▼ −3.87% | ▼ −5.00% | $109.78 (+5.59%) |
|
Feb 25, 2026
15w ago
|
8-K
| $87.10 $94.83 | ▲ +8.87% | ▲ +9.97% | $109.78 (+26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access